問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳慶蘭

Recruiting

List

4Cases

2024-05-09 - 2027-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-01-01 - 2031-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2020-03-22 - 2023-09-29

Phase II

A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)

  • Condition/Disease

    Relapsed or Refractory Osteosarcoma

  • Test Drug

    Lenvima Capsules 1mg, 4mg, 10mg; Etoposide 100 mg HEXAL, 20 mg/mL; Ifosfamide for injection

Participate Sites
2Sites

Recruiting2Sites

2019-12-01 - 2023-10-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB